Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.

Galactionova K, Loibl S, Salari P, Marmé F, Martin M, Untch M, Bonnefoi HR, Kim SB, Bear HD, McCarthy N, Gelmon KA, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Gnant M, Makris A, Burchardi N, Schwenkglenks M

Open source

DOI: 10.3389/fonc.2022.886831
Published: 2022
Container: Frontiers in oncology
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2022.886831,
  title = {Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.},
  author = {Galactionova K and Loibl S and Salari P and Marmé F and Martin M and Untch M and Bonnefoi HR and Kim SB and Bear HD and McCarthy N and Gelmon KA and García-Sáenz JA and Kelly CM and Reimer T and Toi M and Rugo HS and Gnant M and Makris A and Burchardi N and Schwenkglenks M},
  year = {2022},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2022.886831},
  url = {https://doi.org/10.3389/fonc.2022.886831}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.
AU  - Galactionova K
AU  - Loibl S
AU  - Salari P
AU  - Marmé F
AU  - Martin M
AU  - Untch M
AU  - Bonnefoi HR
AU  - Kim SB
AU  - Bear HD
AU  - McCarthy N
AU  - Gelmon KA
AU  - García-Sáenz JA
AU  - Kelly CM
AU  - Reimer T
AU  - Toi M
AU  - Rugo HS
AU  - Gnant M
AU  - Makris A
AU  - Burchardi N
AU  - Schwenkglenks M
PY  - 2022
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2022.886831
UR  - https://doi.org/10.3389/fonc.2022.886831
ER  -

APA

K, G., S, L., P, S., F, M., M, M., M, U., HR, B., SB, K., HD, B., N, M., KA, G., JA, G., CM, K., T, R., M, T., HS, R., M, G., A, M., N, B., & M, S. (2022). Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.. Frontiers in oncology. https://doi.org/10.3389/fonc.2022.886831

Source records

pubmed · retrieved 2026-09-26T12:26:33.738Z
europe-pmc · retrieved 2026-09-26T12:26:33.743Z
doaj · retrieved 2026-09-26T12:26:33.709Z